Rapid, direct effects of statin treatment on arterial redox state and nitric oxide bioavailability in human atherosclerosis via tetrahydrobiopterin- mediated endothelial nitric oxide synthase coupling

Circulation

Volumn 124, Issue 3, 2011, Pages 335-345

  Antoniades, Charalambos ^a,b   Bakogiannis, Constantinos ^b   Leeson, Paul ^a   Guzik, Tomasz J ^c   Zhang, Mei Hua ^a   Tousoulis, Dimitris ^b   Antonopoulos, Alexios S ^b   Demosthenous, Michael ^b   Marinou, Kyriakoula ^b   Hale, Ashley ^a   Paschalis, Andreas ^b,c,d   Psarros, Costas ^b   Triantafyllou, Costas ^d   Bendall, Jennifer ^a   Casadei, Barbara ^a   Stefanadis, Christodoulos ^b   Channon, Keith M ^a  

^a UNIVERSITY OF OXFORD   (United Kingdom)

^b UNIVERSITY OF ATHENS   (Greece)

^c JAGIELLONIAN UNIVERSITY   (Poland)

^d HIPPOKRATION HOSPITAL   (Greece)

Author keywords

nitric oxide synthase; oxidative stress; statins; superoxide; tetrahydrobiopterin

Indexed keywords

ATORVASTATIN; ENDOTHELIAL NITRIC OXIDE SYNTHASE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN; MEVALONIC ACID; NITRIC OXIDE; PLACEBO; TETRAHYDROBIOPTERIN;

ADULT; AGED; ARTICLE; ATHEROSCLEROSIS; BIOAVAILABILITY; CLINICAL ARTICLE; CONTROLLED STUDY; CORONARY ARTERY BYPASS GRAFT; CORONARY ARTERY DISEASE; DOUBLE BLIND PROCEDURE; DRUG EFFECT; ENZYME INHIBITION; FEMALE; HUMAN; INTERNAL MAMMARY ARTERY; MALE; OXIDATION REDUCTION REACTION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

AGED; BIOLOGICAL AVAILABILITY; BIOPTERIN; CORONARY ARTERY BYPASS; CORONARY ARTERY DISEASE; CORONARY VESSELS; DOUBLE-BLIND METHOD; ENDOTHELIUM, VASCULAR; FEMALE; HEPTANOIC ACIDS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MALE; MIDDLE AGED; NITRIC OXIDE; NITRIC OXIDE SYNTHASE TYPE III; OXIDATION-REDUCTION; OXIDATIVE COUPLING; OXYGEN; PYRROLES; SUPEROXIDES;

EID: 79961031512     PISSN: 00097322     EISSN: 15244539     Source Type: Journal    
DOI: 10.1161/CIRCULATIONAHA.110.985150     Document Type: Article

References (35)

1. Ridker PM, Danielson E, Fonseca FA, Genest J, Gotto AM Jr, Kastelein JJ, Koenig W, Libby P, Lorenzatti AJ, Macfadyen JG, Nordestgaard BG, Shepherd J, Willerson JT, Glynn RJ. Reduction in C-reactive protein and LDL cholesterol and cardiovascular event rates after initiation of rosuvastatin: a prospective study of the JUPITER trial. Lancet. 2009;373:1175-1182.
2. Ridker PM, Cannon CP, Morrow D, Rifai N, Rose LM, McCabe CH, Pfeffer MA, Braunwald E. C-reactive protein levels and outcomes after statin therapy. N Engl J Med. 2005;352:20-28. (Pubitemid 40075677)
3. Sorrentino S, Landmesser U. Nonlipid-lowering effects of statins. Curr Treat Options Cardiovasc Med. 2005;7:459-466. (Pubitemid 41749009)
4. Zhou Q, Liao JK. Pleiotropic effects of statins: basic research and clinical perspectives. Circ J. 74:818-826.
5. Antoniades C, Antonopoulos AS, Bendall JK, Channon KM. Targeting redox signaling in the vascular wall: from basic science to clinical practice. Curr Pharm Des. 2009;15:329-342.
6. Osto E, Coppolino G, Volpe M, Cosentino F. Restoring the dysfunctional endothelium. Curr Pharm Des. 2007;13:1053-1068. (Pubitemid 46696560)
7. Rawlings R, Nohria A, Liu PY, Donnelly J, Creager MA, Ganz P, Selwyn A, Liao JK. Comparison of effects of rosuvastatin (10 mg) versus atorvastatin (40 mg) on rho kinase activity in Caucasian men with a previous atherosclerotic event. Am J Cardiol. 2009;103:437-441.
8. Taylor AJ, Villines TC, Stanek EJ, Devine PJ, Griffen L, Miller M, Weissman NJ, Turco M. Extended-release niacin or ezetimibe and carotid intima-media thickness. N Engl J Med. 2009;361:2113-2122.
9. Landmesser U, Bahlmann F, Mueller M, Spiekermann S, Kirchhoff N, Schulz S, Manes C, Fischer D, de Groot K, Fliser D, Fauler G, Marz W, Drexler H. Simvastatin versus ezetimibe: pleiotropic and lipid-lowering effects on endothelial function in humans. Circulation. 2005;111:2356-2363. (Pubitemid 40647072)
10. Blackwell KA, Sorenson JP, Richardson DM, Smith LA, Suda O, Nath K, Katusic ZS. Mechanisms of aging-induced impairment of endotheliumdependent relaxation: role of tetrahydrobiopterin. Am J Physiol Heart Circ Physiol. 2004;287:H2448-H2453. (Pubitemid 39557113)
11. Guzik TJ, Mussa S, Gastaldi D, Sadowski J, Ratnatunga C, Pillai R, Channon KM. Mechanisms of increased vascular superoxide production in human diabetes mellitus: role of NAD (P) H oxidase and endothelial nitric oxide synthase. Circulation. 2002;105:1656-1662. (Pubitemid 34298608)
12. Antoniades C, Shirodaria C, Crabtree M, Rinze R, Alp N, Cunnington C, Diesch J, Tousoulis D, Stefanadis C, Leeson P, Ratnatunga C, Pillai R, Channon KM. Altered plasma versus vascular biopterins in human atherosclerosis reveal relationships between endothelial nitric oxide synthase coupling, endothelial function, and inflammation. Circulation. 2007;116:2851-2859. (Pubitemid 350291226)
13. Landmesser U, Dikalov S, Price SR, McCann L, Fukai T, Holland SM, Mitch WE, Harrison DG. Oxidation of tetrahydrobiopterin leads to uncoupling of endothelial cell nitric oxide synthase in hypertension. J Clin Invest. 2003;111:1201-1209. (Pubitemid 36519937)
14. Antoniades C, Shirodaria C, Warrick N, Shijie C, DeBono J, Lee J, Leeson P, Neubauer S, Ratnatunga C, Pillai R, Refsum H, Channon K. 5- Methyltetrahydrofolate rapidly improves endothelial function and decreases superoxide production in human vessels: effects on vascular tetrahydrobiopterin availability and eNOS coupling. Circulation. 2006;114:1193-1201. (Pubitemid 44386484)
15. Cosentino F, Hurlimann D, Delli Gatti C, Chenevard R, Blau N, Alp NJ, Channon KM, Eto M, Lerch P, Enseleit F, Ruschitzka F, Volpe M, Luscher TF, Noll G. Chronic treatment with tetrahydrobiopterin reverses endothelial dysfunction and oxidative stress in hypercholesterolaemia. Heart. 2008;94:487-492. (Pubitemid 351441407)
16. Maier W, Cosentino F, Lutolf RB, Fleisch M, Seiler C, Hess OM, Meier B, Luscher TF. Tetrahydrobiopterin improves endothelial function in patients with coronary artery disease. J Cardiovasc Pharmacol. 2000;35:173-178. (Pubitemid 30073806)
17. Katusic ZS, d'Uscio LV, Nath KA. Vascular protection by tetrahydrobiopterin: progress and therapeutic prospects. Trends Pharmacol Sci. 2009;30:48-54.
18. Hattori Y, Hattori S, Wang X, Satoh H, Nakanishi N, Kasai K. Oral administration of tetrahydrobiopterin slows the progression of atherosclerosis in apolipoprotein E-knockout mice. Arterioscler Thromb Vasc Biol. 2007;27:865-870. (Pubitemid 46606718)
19. Cangemi R, Loffredo L, Carnevale R, Perri L, Patrizi MP, Sanguigni V, Pignatelli P, Violi F. Early decrease of oxidative stress by atorvastatin in hypercholesterolaemic patients: effect on circulating vitamin E. Eur Heart J. 2008;29:54-62.
20. Otto A, Fontaine J, Tschirhart E, Fontaine D, Berkenboom G. Rosuvastatin treatment protects against nitrate-induced oxidative stress in eNOS knockout mice: implication of the NAD (P) H oxidase pathway. Br J Pharmacol. 2006;148:544-552. (Pubitemid 43882091)
21. Rueckschloss U, Galle J, Holtz J, Zerkowski HR, Morawietz H. Induction of NAD (P) H oxidase by oxidized low-density lipoprotein in human endothelial cells: antioxidative potential of hydroxymethylglutaryl coenzyme A reductase inhibitor therapy. Circulation. 2001;104:1767-1772. (Pubitemid 32963340)
22. Hattori Y, Nakanishi N, Akimoto K, Yoshida M, Kasai K. HMG-CoA reductase inhibitor increases GTP cyclohydrolase I mRNA and tetrahydrobiopterin in vascular endothelial cells. Arterioscler Thromb Vasc Biol. 2003;23:176-182. (Pubitemid 36231925)
23. Liu PY, Liu YW, Lin LJ, Chen JH, Liao JK. Evidence for statin pleiotropy in humans: differential effects of statins and ezetimibe on rho-associated coiled-coil containing protein kinase activity, endothelial function, and inflammation. Circulation. 2009;119:131-138.
24. Third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation. 2002;106:3143-3421.
25. Antoniades C, Bakogiannis C, Tousoulis D, Reilly S, Zhang MH, Paschalis A, Antonopoulos A, Demosthenous M, Miliou A, Psarros C, Marinou K, Sfyras N, Economopoulos G, Casadei B, Channon KM, Stefanadis C. Preoperative atorvastatin treatment in CABG patients rapidly improves vein graft redox state by inhibition of Rac1 and NADPH-oxidase activity preoperative atorvastatin treatment in CABG patients rapidly improves vein. Circulation. 2010;122:S66-S73.
26. Wang CY, Liu PY, Liao JK. Pleiotropic effects of statin therapy: molecular mechanisms and clinical results. Trends Mol Med. 2008;14:37-44.
27. Laufs U, La Fata V, Plutzky J, Liao JK. Upregulation of endothelial nitric oxide synthase by HMG CoA reductase inhibitors. Circulation. 1998;97:1129-1135. (Pubitemid 28152885)
28. Laufs U, Liao JK. Post-transcriptional regulation of endothelial nitric oxide synthase mRNA stability by Rho GTPase. J Biol Chem. 1998;273:24266-24271. (Pubitemid 28435775)
29. Morawietz H, Erbs S, Holtz J, Schubert A, Krekler M, Goettsch W, Kuss O, Adams V, Lenk K, Mohr FW, Schuler G, Hambrecht R. Endothelial protection, AT1 blockade and cholesterol-dependent oxidative stress: the EPAS trial. Circulation. 2006;114(suppl):I-296-I-301. (Pubitemid 44297166)
30. Mason RP, Kubant R, Heeba G, Jacob RF, Day CA, Medlin YS, Funovics P, Malinski T. Synergistic effect of amlodipine and atorvastatin in reversing LDL-induced endothelial dysfunction. Pharm Res. 2008;25:1798-1806.
31. Wenzel P, Daiber A, Oelze M, Brandt M, Closs E, Xu J, Thum T, Bauersachs J, Ertl G, Zou MH, Forstermann U, Munzel T. Mechanisms underlying recoupling of eNOS by HMG-CoA reductase inhibition in a rat model of streptozotocin-induced diabetes mellitus. Atherosclerosis. 2008;198:65-76.
32. Matsuda N, Hayashi Y, Takahashi Y, Hattori Y. Phosphorylation of endothelial nitric-oxide synthase is diminished in mesenteric arteries from septic rabbits depending on the altered phosphatidylinositol 3-kinase/Akt pathway: reversal effect of fluvastatin therapy. J Pharmacol Exp Ther. 2006;319:1348-1354.
33. Crabtree MJ, Tatham AL, Al-Wakeel Y, Warrick N, Hale AB, Cai S, Channon KM, Alp NJ. Quantitative regulation of intracellular endothelial nitric-oxide synthase (eNOS) coupling by both tetrahydrobiopterin-eNOS stoichiometry and biopterin redox status: insights from cells with tetregulated GTP cyclohydrolase I expression. J Biol Chem. 2009;284:1136-1144.
34. Antoniades C, Shirodaria C, Van Assche T, Cunnington C, Tegeder I, Lotsch J, Guzik TJ, Leeson P, Diesch J, Tousoulis D, Stefanadis C, Costigan M, Woolf CJ, Alp NJ, Channon KM. GCH1 haplotype determines vascular and plasma biopterin availability in coronary artery disease effects on vascular superoxide production and endothelial function. J Am Coll Cardiol. 2008;52:158-165. (Pubitemid 351885444)
35. Kosmidou I, Moore JP, Weber M, Searles CD. Statin treatment and 3' polyadenylation of eNOS mRNA. Arterioscler Thromb Vasc Biol. 2007;27:2642-2649. (Pubitemid 350158917)